Loading...
•
Jun 30, 2023
Tenaya Therapeutics Q2 2023 Earnings Report
Reported second quarter 2023 financial results and provided a business update.
Key Takeaways
Tenaya Therapeutics reported financial results for the second quarter ended June 30, 2023. The company's cash, cash equivalents and investments were $151.6 million as of June 30, 2023, expected to fund operations into the first half of 2025. The company anticipates dosing its first patient in the Phase 1b trial of TN-201 during the third quarter of 2023 and plans to submit an IND application for TN-401 in the second half of 2023.
Dosing of first patient in Phase 1b trial of TN-201 on track to occur in Q3 2023.
Data from Phase 1 clinical trial of TN-301 accepted for presentation at HFSA 2023.
IND Application for TN-401 anticipated in second half 2023.
Second Quarter Cash and Investments of $151.6 Million; Runway to Fund Operations into First Half 2025.
Tenaya Therapeutics
Tenaya Therapeutics
Forward Guidance
Tenaya expects current cash, cash equivalents and investments in marketable securities will be sufficient to fund the company into the first half of 2025.